Paul Moore
Last active: 2/17/2015


My work is focused on understanding the molecular basis of genetic variations in asthma. Over the past decade, a number of candidate genes have been linked to asthma. Despite these linkage studies, the mechanistic basis of how genetic variation results in an asthma phenotype is not well understood. For our in vitro studies, we utilize cultured human airway smooth muscle (HASM) cells, isolated from the trachealis muscle of lung transplant donors since airway smooth muscle is the primary target of bronchodilators used to treat asthma. My primary focus been on variation in the Beta-2-adrenergic receptor (ADRB2) gene. We have demonstrated that polymorphisms in the regulatory and coding regions of ADRB2 influence desensitization in HASM, and we are trying to demonstrate the mechanisms by which polymorphisms result in functional changes. Our approach includes a combination of pharmacokinetic and molecular techniques, including promoter bashing, receptor binding, and measurements of relevant signaling pathways. With better understanding of the ADRB2 gene, we hope to establish a paradigm by which genetic variability in other G protein coupled receptors alters airway smooth muscle responses. We have demonstrated that genetic variability in the IL-4 receptor alters responses in the Th2 signaling pathway, including TARC expression and eotaxin release. Furthermore, we have shown that responses to corticosteroids in HASM vary by ADRB2 genotype and by IL-4R genotype in the absence of variability in known glucocorticoid-response-elements, suggesting a novel signaling pathway by which corticosteroids influence HASM responses. The results of our in vitro observations have direct clinical application. I am directly involved in establishing a cohort of children with severe asthma admitted to the Pediatric Intensive Care Unit for an asthma exacerbation. Our project is focused on identifying genetic factors that influence ethnic disparities in severe pediatric asthma. In the Center for Human Genetics, we are using the latest analytical tools to understand the influence of gene-gene and gene-enviroment interactions that lead to severe asthma.A number of follow up studies are being generated based on our preliminary questions. We plan to look at follow up of those patients in the Pediatric Continuity Clinic, and also bring a group back to the GCRC to understand whether physiologic differences persist beyond the acute exacerbation. In addition, we are looking at a cohort of adults hospitalized with an asthma exacerbation.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Childhood interstitial lung diseases: an 18-year retrospective analysis. Soares JJ, Deutsch GH, Moore PE, Fazili MF, Austin ED, Brown RF, Sokolow AG, Hilmes MA, Young LR (2013) Pediatrics 132(4): 684-91
    › Primary publication · 24081995 (PubMed) · PMC3784299 (PubMed Central)
  2. The dilemma of albuterol dosing for acute asthma exacerbations in pediatric patients. Arnold DH, Moore PE, Abramo TJ, Hartert TV (2011) Chest 139(2): 472
    › Primary publication · 21285065 (PubMed) · PMC3032370 (PubMed Central)
  3. Influence of gene-gene interactions on response to albuterol therapy. Moore PE (2011) Pharmacogenomics 12(1): 1-3
    › Primary publication · 21174616 (PubMed)
  4. Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. Crossno PF, Polosukhin VV, Blackwell TS, Johnson JE, Markin C, Moore PE, Worrell JA, Stahlman MT, Phillips JA, Loyd JE, Cogan JD, Lawson WE (2010) Chest 137(4): 969-73
    › Primary publication · 20371530 (PubMed) · PMC2851554 (PubMed Central)
  5. A retrospective characterization of African- and European American asthmatic children in a pediatric critical care unit. Files DC, Patel N, Gebretsadik T, Moore PE, Sheller J (2009) J Natl Med Assoc 101(11): 1119-24
    › Primary publication · 19998640 (PubMed)
  6. Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma. Moore PE, Ryckman KK, Williams SM, Patel N, Summar ML, Sheller JR (2009) Pediatr Pulmonol 44(7): 649-54
    › Primary publication · 19514054 (PubMed)
  7. The clinical impact of the radiology report in wheezing and nonwheezing febrile children: a survey of clinicians. Spottswood SE, Liaw K, Hernanz-Schulman M, Hilmes MA, Moore PE, Patterson B, Chen H, Kan JH (2009) Pediatr Radiol 39(4): 348-53
    › Primary publication · 19241075 (PubMed)
  8. Exploration of the beta2-adrenergic receptor regulatory regions: the next step in the holy grail of asthma pharmacogenetics research. Moore PE (2008) Am J Physiol Lung Cell Mol Physiol 294(2): L187-9
    › Primary publication · 18065655 (PubMed)
  9. Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. Singh AM, Moore PE, Gern JE, Lemanske RF, Hartert TV (2007) Am J Respir Crit Care Med 175(2): 108-19
    › Primary publication · 17053206 (PubMed)
  10. Respiratory syncytial virus infection reduces beta2-adrenergic responses in human airway smooth muscle. Moore PE, Cunningham G, Calder MM, DeMatteo AD, Peeples ME, Summar ML, Peebles RS (2006) Am J Respir Cell Mol Biol 35(5): 559-64
    › Primary publication · 16763224 (PubMed) · PMC2643275 (PubMed Central)
  11. Oncostatin M causes eotaxin-1 release from airway smooth muscle: synergy with IL-4 and IL-13. Faffe DS, Flynt L, Mellema M, Moore PE, Silverman ES, Subramaniam V, Jones MR, Mizgerd JP, Whitehead T, Imrich A, Panettieri RA, Shore SA (2005) J Allergy Clin Immunol 115(3): 514-20
    › Primary publication · 15753898 (PubMed)
  12. Regulation of beta-adrenergic responses in airway smooth muscle. Shore SA, Moore PE (2003) Respir Physiol Neurobiol 137(2-3): 179-95
    › Primary publication · 14516725 (PubMed)
  13. IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype. Faffe DS, Whitehead T, Moore PE, Baraldo S, Flynt L, Bourgeois K, Panettieri RA, Shore SA (2003) Am J Physiol Lung Cell Mol Physiol 285(4): L907-14
    › Primary publication · 12871855 (PubMed)
  14. Effect of dexamethasone on beta2-adrenergic desensitization in airway smooth muscle: role of the ARG19 polymorphism. Moore PE, Calder MM, Silverman ES, Panettieri RA, Shore SA (2003) Chest 123(3 Suppl): 368S-9S
    › Primary publication · 12628978 (PubMed)
  15. Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Baraldo S, Faffe DS, Moore PE, Whitehead T, McKenna M, Silverman ES, Panettieri RA, Shore SA (2003) Am J Physiol Lung Cell Mol Physiol 284(6): L1093-102
    › Primary publication · 12588703 (PubMed)
  16. Effect of IL-1beta on CRE-dependent gene expression in human airway smooth muscle cells. Lahiri T, Moore PE, Baraldo S, Whitehead TR, McKenna MD, Panettieri RA, Shore SA (2002) Am J Physiol Lung Cell Mol Physiol 283(6): L1239-46
    › Primary publication · 12388341 (PubMed)
  17. Effects of cytokines on contractile and dilator responses of airway smooth muscle. Shore SA, Moore PE (2002) Clin Exp Pharmacol Physiol 29(10): 859-66
    › Primary publication · 12207563 (PubMed)